Insider Selling: AxoGen (NASDAQ:AXGN) Director Sells 5,347 Shares of Stock

AxoGen, Inc. (NASDAQ:AXGN) Director William Mr. Burke sold 5,347 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $24.01, for a total transaction of $128,381.47. Following the completion of the transaction, the director owned 100 shares of the company’s stock, valued at approximately $2,401. The trade was a 98.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

AxoGen Stock Down 1.8%

Shares of NASDAQ AXGN traded down $0.42 on Friday, reaching $23.57. 989,751 shares of the company’s stock traded hands, compared to its average volume of 846,646. The business’s 50 day simple moving average is $17.74 and its two-hundred day simple moving average is $14.44. AxoGen, Inc. has a 12 month low of $9.22 and a 12 month high of $24.25. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -471.40 and a beta of 1.09. The company has a quick ratio of 2.67, a current ratio of 4.14 and a debt-to-equity ratio of 0.59.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.03. AxoGen had a negative return on equity of 1.96% and a negative net margin of 0.98%.The company had revenue of $60.08 million for the quarter, compared to the consensus estimate of $56.90 million. AxoGen has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that AxoGen, Inc. will post -0.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AXGN has been the subject of several recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of AxoGen in a research report on Wednesday, October 29th. Citizens Jmp lifted their target price on shares of AxoGen from $26.00 to $34.00 and gave the stock a “market outperform” rating in a report on Thursday, October 30th. Raymond James Financial upped their target price on shares of AxoGen from $20.00 to $27.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. Wall Street Zen raised shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, Citigroup restated a “market outperform” rating on shares of AxoGen in a report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, AxoGen has a consensus rating of “Moderate Buy” and an average target price of $28.86.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Future Financial Wealth Managment LLC purchased a new stake in AxoGen in the third quarter worth approximately $27,000. State of Alaska Department of Revenue purchased a new stake in AxoGen during the 3rd quarter valued at $43,000. AdvisorNet Financial Inc lifted its holdings in shares of AxoGen by 500.0% during the 3rd quarter. AdvisorNet Financial Inc now owns 4,800 shares of the medical equipment provider’s stock valued at $86,000 after buying an additional 4,000 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of AxoGen by 189.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock worth $55,000 after buying an additional 3,327 shares during the last quarter. Finally, AlphaQuest LLC grew its holdings in shares of AxoGen by 882.2% in the second quarter. AlphaQuest LLC now owns 6,276 shares of the medical equipment provider’s stock worth $68,000 after acquiring an additional 5,637 shares during the period. 80.29% of the stock is owned by hedge funds and other institutional investors.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.